Suppr超能文献

[出血性大疱性皮肤病(HBD):肝素的一种罕见副作用]

[Hemorrhagic bullous dermatosis (HBD): A rare side-effect of heparins].

作者信息

Gérard A, Levavasseur M, Gaboriau L, Stichelbout M, Staumont-Salle D

机构信息

Service de dermatologie, hôpital Claude-Huriez, CHU de Lille, 59000 Lille, France; Université de Lille, 59000 Lille, France.

Service de dermatologie, hôpital Claude-Huriez, CHU de Lille, 59000 Lille, France; Université de Lille, 59000 Lille, France.

出版信息

Ann Dermatol Venereol. 2020 Jun-Jul;147(6-7):446-450. doi: 10.1016/j.annder.2019.08.021. Epub 2020 Jan 28.

Abstract

BACKGROUND

Bullous haemorrhagic dermatosis (BHD) induced by heparin is a rare and benign side effect of which we report two cases.

PATIENTS AND METHODS

Case 1: an 81-year-old man presented haemorrhagic bullae on the limbs and trunk 7 days after starting enoxaparin. The laboratory haemostasis assessment was normal. A diagnosis was made of BHD induced by enoxaparin and the patient's treatment was switched to apixaban, resulting in a favourable outcome with resolution of the lesions within 15 days. Case 2: a 71-year-old woman hospitalised for pulmonary embolism was given tinzaparin. At two months of treatment, haemorrhagic bullae were observed on her forearms at distance from the injection sites. A diagnosis of BHD induced by tinzaparin was made. Treatment with tinzaparin was continued and the lesions resolved within 15 days.

DISCUSSION

Heparin-induced BHD is a rare entity initially described in 2006. Ninety-five cases of heparin-induced BHD have been reported. It is characterized by multiple haemorrhagic bullae at a distance from the injection sites. Time to onset of lesions after heparin initiation ranges from 24h to 4 months. Laboratory assessment should be routinely performed to rule out any haemostasis disorders. Lesions subside within 15 days whether heparin is continued or withdrawn.

CONCLUSION

Heparin-induced BHD is a rare but benign side effect of heparins. In the absence of recommendations, therapeutic management should be adapted to the individual situation.

摘要

背景

肝素诱导的大疱性出血性皮肤病(BHD)是一种罕见的良性副作用,我们报告两例。

患者与方法

病例1:一名81岁男性在开始使用依诺肝素7天后,四肢和躯干出现出血性大疱。实验室止血评估正常。诊断为依诺肝素诱导的BHD,患者的治疗改为阿哌沙班,15天内病变消退,预后良好。病例2:一名因肺栓塞住院的71岁女性接受了替扎肝素治疗。治疗两个月时,在其前臂远离注射部位处观察到出血性大疱。诊断为替扎肝素诱导的BHD。继续使用替扎肝素治疗,病变在15天内消退。

讨论

肝素诱导的BHD是一种罕见病症,最初于2006年被描述。已报告95例肝素诱导的BHD。其特征是在远离注射部位处出现多个出血性大疱。肝素开始使用后病变出现的时间为24小时至4个月。应常规进行实验室评估以排除任何止血障碍。无论继续使用还是停用肝素,病变都会在15天内消退。

结论

肝素诱导的BHD是肝素罕见但良性的副作用。在缺乏相关建议的情况下,治疗管理应根据个体情况进行调整。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验